Xenon Pharmaceuticals INC Form 4 insider transactions

Steven Gannon, a Director of Xenon Pharmaceuticals Inc., sold 10,000 shares of common stock on August 11, 2026 for $64.06 per share.

Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals to cover tax obligations related to RSU vesting.

Xenon Pharmaceuticals Director Gillian Cannon sold 1,190 common shares to cover tax obligations related to RSU vesting.

Director Gary Patou exercised restricted share units and received new equity grants in Xenon Pharmaceuticals.

Director Patrick Machado acquired common shares through RSU vesting and received new equity grants.

Director Justin D. Gover reported the vesting of restricted share units and the acquisition of new equity awards.

Director Elizabeth A. Garofalo acquired common shares through RSU vesting and received new equity grants.

Director Steven Gannon acquired common shares through RSU vesting and received new equity grants in Xenon Pharmaceuticals.

Xenon Pharmaceuticals Director Gillian Cannon reported the vesting of restricted share units and the grant of new stock options and RSUs, increasing her beneficial ownership.

Director Dawn Svoronos reported the vesting of restricted share units and the receipt of new equity grants in Xenon Pharmaceuticals.

Director Steven Gannon acquired 3,500 common shares of Xenon Pharmaceuticals through the exercise of stock options at $7.38 per share.

Xenon Pharmaceuticals' Chief Medical Officer, Christopher John Kenney, sold 1,410 common shares for tax purposes following the vesting of 3,750 restricted share units.

Xenon Pharmaceuticals' Chief Legal Officer, Andrea DiFabio, sold shares to cover tax obligations following the vesting of restricted stock units.

Xenon Pharmaceuticals Inc.'s President and CEO, Ian Mortimer, reported the vesting of 12,500 restricted share units and a subsequent sale of 7,308 common shares to cover tax obligations.

Xenon Pharmaceuticals' Chief Medical Officer, Christopher John Kenney, was granted 120,000 equity awards, including stock options and restricted share units, effective January 9, 2026.

Xenon Pharmaceuticals' Chief Commercial Officer, Darren S. Cline, was granted 40,000 stock options and 20,000 restricted share units.

Xenon Pharmaceuticals' Chief Legal Officer, Andrea DiFabio, received significant equity awards including 80,000 stock options and 15,000 restricted share units.

Xenon Pharmaceuticals Inc. President and CEO, Ian Mortimer, was granted 350,000 stock options and 65,000 restricted share units on January 9, 2026.

Xenon Pharmaceuticals' President & CEO, Ian Mortimer, exercised stock options and subsequently sold 40,000 common shares under a pre-arranged trading plan.

Xenon Pharmaceuticals Inc.'s President and CEO, Ian Mortimer, sold a total of 25,205 common shares in December 2025 under a pre-arranged 10b5-1 trading plan.

Xenon Pharmaceuticals Inc.'s President and CEO, Ian Mortimer, sold 97 common shares for $45.01 each on November 28, 2025, as part of a pre-arranged 10b5-1 trading plan.

Xenon Pharmaceuticals Inc. Chief Financial Officer Thomas Patrick Kelly was granted 225,000 share options and 30,000 restricted share units on October 15, 2025.

Xenon Pharmaceuticals' President, CEO, and Interim CFO, Ian Mortimer, sold 25,000 common shares for a weighted-average price of $40.16 after exercising options at $7.69.

Xenon Pharmaceuticals Inc. has granted 185,800 share options to its Chief Commercial Officer, Darren S. Cline, as part of his compensation package.

Xenon Pharmaceuticals Inc. Director Gary Patou has acquired 17,012 share options and 2,645 restricted share units, aligning his interests with the company's long-term performance.

Xenon Pharmaceuticals Inc. Director Patrick Machado has acquired 17,012 share options and 2,645 restricted share units, aligning his interests with the company's future performance.

Xenon Pharmaceuticals Inc. Director Justin D. Gover was granted 17,012 share options and 2,645 restricted share units on June 5, 2025, as reported in a recent SEC Form 4 filing.

Xenon Pharmaceuticals Inc. Director Elizabeth A. Garofalo was granted 17,012 stock options and 2,645 restricted share units as part of her compensation, aligning her interests with shareholders.

Xenon Pharmaceuticals Inc. Director Steven Gannon has increased his beneficial ownership through the acquisition of stock options and restricted share units, aligning his interests with long-term shareholder value.

Xenon Pharmaceuticals Inc. Director Gillian Cannon has reported the acquisition of 17,012 share options and 2,645 restricted share units as part of her compensation, aligning her interests with shareholders.